Kleinerman ES - Search Results

1

Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.

Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Kleinerman ES, et al. J Clin Oncol. 1992 Aug;10(8):1310-6. doi: 10.1200/JCO.1992.10.8.1310. J Clin Oncol. 1992. PMID: 1634921 Clinical Trial.

2

Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents.

Killion JJ, Kleinerman ES, Wilson MR, Tanaka M, Fidler IJ. Killion JJ, et al. Among authors: kleinerman es. Oncol Res. 1992;4(10):413-8. Oncol Res. 1992. PMID: 1292756

3

Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid).

Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakoff IH, Benjamin R, Fidler IJ. Kleinerman ES, et al. Cancer Immunol Immunother. 1992;34(4):211-20. doi: 10.1007/BF01741788. Cancer Immunol Immunother. 1992. PMID: 1537053 Free PMC article. Clinical Trial.

4

Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.

Maeda M, Knowles RD, Kleinerman ES. Maeda M, et al. Among authors: kleinerman es. Cancer Commun. 1991;3(10-11):313-21. doi: 10.3727/095535491820873740. Cancer Commun. 1991. PMID: 1722107

5

Antitumor activity of TNF-alpha, IL-1, and IFN-gamma against three human osteosarcoma cell lines.

Jia SF, Kleinerman ES. Jia SF, et al. Among authors: kleinerman es. Lymphokine Cytokine Res. 1991 Aug;10(4):281-4. Lymphokine Cytokine Res. 1991. PMID: 1932372

6

Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.

Kleinerman ES, Snyder JS, Jaffe N. Kleinerman ES, et al. J Clin Oncol. 1991 Feb;9(2):259-67. doi: 10.1200/JCO.1991.9.2.259. J Clin Oncol. 1991. PMID: 1988574

7

Differential release of TNF-alpha, IL 1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents.

Fidler IJ, Nii A, Utsugi T, Brown D, Bakouche O, Kleinerman ES. Fidler IJ, et al. Among authors: kleinerman es. Lymphokine Res. 1990 Winter;9(4):449-63. Lymphokine Res. 1990. PMID: 2090873

8

Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.

Kleinerman ES, Jaffe N. Kleinerman ES, et al. Prog Clin Biol Res. 1990;343:263-79. Prog Clin Biol Res. 1990. PMID: 2198583 Clinical Trial. No abstract available.

9

Effect of recombinant human interleukin 4 on human monocyte activity.

Hudson MM, Markowitz AB, Gutterman JU, Knowles RD, Snyder JS, Kleinerman ES. Hudson MM, et al. Among authors: kleinerman es. Cancer Res. 1990 Jun 1;50(11):3154-8. Cancer Res. 1990. PMID: 2334911

10

Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.

Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, et al. Murray JL, et al. Among authors: kleinerman es. J Clin Oncol. 1989 Dec;7(12):1915-25. doi: 10.1200/JCO.1989.7.12.1915. J Clin Oncol. 1989. PMID: 2479721

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

224 results

Search Page

Filters